Effect of 1 alpha-hydroxyvitamin D3 on serum levels of thyroid hormones in hyperthyroid patients with untreated Graves' disease (Q42547328)

2 November 2017

Effect of 1 alpha-hydroxyvitamin D3 on serum levels of thyroid hormones in hyperthyroid patients with untreated Graves' disease (English)

1 reference

2 November 2017

T Kawakami-Tani

1

1 reference

2 November 2017

E Fukawa

2

1 reference

2 November 2017

H Tanaka

3

1 reference

2 November 2017

Y Abe

4

1 reference

2 November 2017

I Makino

5

1 reference

2 November 2017

1 October 1997

1 reference

2 November 2017

5

1 reference

based on heuristic

inferred from page(s)

published in

Metabolism

1 reference

2 November 2017

46

1 reference

2 November 2017

10

1 reference

2 November 2017

1184-1188

1 reference

Changes in Thyroid-Stimulating Immunoglobulins during Antithyroid Therapy*

2 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2897%2990214-6

Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2897%2990214-6

Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2897%2990214-6

ANCA-associated vasculitis and lupus-like syndrome caused by methimazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2897%2990214-6

Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with anti-thyroid drug treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2897%2990214-6

Myeloperoxidase-antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis complicating the course of Graves' disease: report of three adult cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2897%2990214-6

Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2897%2990214-6

Comparison of Effects of High and Low Dosage Regimens of Antithyroid Drugs in the Management of Graves’ Hyperthyroidism*

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2897%2990214-6

Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2897%2990214-6

Paracrine role for calcitriol in the immune system and skin creates new therapeutic possibilities for vitamin D analogs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2897%2990214-6

In vivo beneficial effects of cyclosporin A and 1,25-dihydroxyvitamin D3 on the induction of experimental autoimmune thyroiditis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2897%2990214-6

Serum levels of vitamin D metabolites and bone remodelling in hyperthyroidism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2897%2990214-6

Thyrotoxic bone disease in women: a potentially reversible disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2897%2990214-6

10.1016/S0026-0495(97)90214-6

7 January 2021

Identifiers

DOI

1 reference

2 November 2017

1 reference